Session Details
[F1]Flash Talks (Odd no.)
Mon. Mar 2, 2026 5:00 PM - 5:40 PM JST
Mon. Mar 2, 2026 8:00 AM - 8:40 AM UTC
Mon. Mar 2, 2026 8:00 AM - 8:40 AM UTC
Kobe Portopia Hotel(South Wing 1F Ohwada)
[F1-1]In vitro induction of human germinal center B-cells
*David Geoffrey Priest1, Wataru Ise2,3, James B. Wing1,3,4 (1. Human Single Cell Immunology Team, Division of Microbiology and Immunology, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, Japan (Japan), 2. Regulation of Host Defense Team, Division of Microbiology and Immunology, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan (Japan), 3. Center for Advanced Modalities and DDS (CAMaD), Osaka University, Osaka, Japan (Japan), 4. Laboratory of Human Single Cell Immunology, World Premier International Research Center Initiative Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Osaka, Japan (Japan))
[F1-3]Biphasic innate immune cell-mediated memory responses confer protection against viral infection
*Asuka Joy Tobuse1,2, Kouji Kobiyama1,3,4, Jun Tsuchida1, Teppei Hara1, Masamitsu N Asaka5, Daichi Utsumi5, Yaeko Nakajima-Takagi8, Mariana Silva Almeida7, Motohiko Oshima8, Tomoya Hayashi1,9,3, Burcu Temizoz1,9,3, Cevayir Coban7,9,3, Yasuhiro Yasutomi5,6, Atsushi Iwama8, Ken J Ishii1,3,9 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 2. Department of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 3. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 4. Division of Rheumatology, Department of medicine, University of California San Diego, La Jolla, California (USA), 5. Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan), 6. Institute for Vaccine Research and Development, Hokkaido University (Japan), 7. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 8. Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo (Japan), 9. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo (Japan))
[F1-5]Prime-Push Mtb Vaccination Drives Immuno-Switching in the Tumor Microenvironment
*Burcu Temizoz1,2,6,7, Nobuyoshi Kobayashi3,2, Yuta Ohira3,2, Areej S1, Kou Hioki1, Mai Onaga1, Tomoya Hayashi1,2,6,7, Michelle Sue Jann Lee5, Takayuki Horii3, Cevayir Coban5,4,7,6, Kouji Kobiyama1,6,8, Ken J. Ishii1,2,4,6,7 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan (Japan), 2. Center for Adjuvant and Vaccine Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8, Osaka, Japan (Japan), 3. Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1 Numagami, Oshikiri, Kumagaya-shi, Saitama, Japan (Japan), 4. WPI Immunology Frontier Research Center (IFReC), Osaka University, 3-3-1, Osaka, Japan (Japan), 5. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, 4-6-1, Tokyo, Japan (Japan), 6. International Vaccine Design Center (VDesC), The Institute of Medical Science (IMSUT), The University of Tokyo, 4-6-1, Tokyo, Japan (Japan), 7. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo 108-8639, Japan. (Japan), 8. Division of Rheumatology, Department of Medicine, University of California San Diego, La Jolla (USA))
[F1-7]Identification of the TCR-mTORC1-TET axis and epigenetic regulators that govern iTreg stability
*Akira Nakajima1, Tatsumasa Hasegawa1, Tomohide Kinoshita1, Toru Kobayashi1, Shohei Hori1 (1. Graduate School of Pharmaceutical Sciences, The University of Tokyo (Japan))
[F1-9]Single-cell analysis reveals age-related diferences in the T cell response to COVID-19 mRNA vaccines
*Ayana Sunami1,2, Norihide Jo1,3, Yoko Hamazaki1,2,4 (1. Center for iPS Cell Research and Application, Kyoto University (Japan), 2. Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University (Japan), 3. Alliance Laboratory for Advanced Medical Research, Graduate School of Medicine, Kyoto University (Japan), 4. Kyoto University Immunomonitoring Center (Japan))
[F1-11]Design of a Universal mRNA T Cell Vaccine Against Multiple Genotypes of Crimean-Congo Haemorrhagic Fever Virus
*Takumi Kawasaki1, Moe Ikegawa1, Yasuteru Sakurai1, Jiro Yasuda1 (1. National Research Center for the Control and Preventation of Infectious Diseases Nagasaki University (Japan))
[F1-13]Independent germinal centers are induced in primary and secondary draining lymph nodes.
*Ryutaro Kotaki1,2,3, Yoshimasa Takahashi2, Takeshi Inoue1,3 (1. The UTOPIA Center, The University of Tokyo (Japan), 2. Research Center for Vaccine Development, NIID, JIHS (Japan), 3. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan))
[F1-15]Transferrin Defines the Microenvironment of Tertiary Lymphoid Structures and Supports the Maintenance of Tissue-Resident Memory T Cells
*Takahisa Hishiya1, Kiyoshi Hirahara1 (1. Department of immunology, Chiba University (Japan))
[F1-17]Human Monoclonal Antibodies Capture Nuanced Antigenic Drift of the H3 Hemagglutines of Seasonal Influenza Viruses
*Calvin Duong1,4, Yui Honjo1, Mifumi Goto1, Jisuk Ko1, David Pattinson5, Lavanya Babujee5, Gabriele Neumann5, Seiya Yamayoshi2,3,4, Yoshihiro Kawaoka1,2,3,4,5 (1. Division of Virology, Institute of Medical Science, University of Tokyo, Japan (Japan), 2. International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo (Japan), 3. Research Center for Global Viral Infections, National Center for Global Health and Medicine Research Institute (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (Japan), 5. Department of Pathobiological Sciences, School of Veterinary Medicine (USA))
[F1-19]A Single-Cell Multi-Omics Approach Reveals Pathogenic Roles and Antigen Specificity of ZEB2-Driven ThA Cells in Systemic Lupus Erythematosus
*Hiroyuki Teruya1, Toshiyuki Ushijima1, Manaka Goto1,2, Hideyuki Takahashi1, Takahiro Itamiya1,2, Hirofumi Shoda3, Haruka Tsuchiya1, Mineto Ota1, Tomohisa Okamura1,2, Keishi Fujio1 (1. Department of Allergy and Rheumatology, Graduation School of Medicine, the University of Tokyo (Japan), 2. Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo (Japan), 3. Department of Rheumatology, Tokyo Medical University Hospital (Japan))
[F1-21]Reduced Antigen-Presenting Cell Function Associated with Lysosomal Dysfunction in Older Adults
*Mengqian Li1, Kohei Kometani1, Norihide Jo1, Yoko Hamazaki1 (1. Kyoto University Center for iPS Cell Research and Application (Japan))
[F1-23]STING involvement in immune responses to tick-borne encephalitis virus
*Moe Ikegawa1, Kentaro Yoshii2, Takumi Kawasaki1 (1. Resarch Unit of Immune Dynamics in Viral Infections ,National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University (Japan), 2. Research Unit of Viral Ecology, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University (Japan))
[F1-25]The role of TBK1 in B cells in the maintenance of chronic germinal centers in Peyer’s Patches at steady-state and during systemic infection
*Mariana Silva Almeida1,2,3, Hiroaki Matsumori1,2,3, Reiko Shinkura3,4, Takeshi Inoue5, Jun Kunisawa6, Ken J Ishii2,3,7, Cevayir Coban1,2,3 (1. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo (Japan), 2. International Vaccine Design Center, Institute of Medical Science (IMSUT), The University of Tokyo (Japan), 3. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo (Japan), 4. Laboratory of Immunology and Infection Control, Research Division for Quantitative Life Sciences (IQB), The University of Tokyo (Japan), 5. Department of Molecular Systems Immunology, The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA) (Japan), 6. Laboratory of Vaccine Materials and Laboratory of Gut Environmental System,Microbial Research Center for Health and Medicine,National Institutes of Biomedical Innovation,Health and Nutrition(NIBIOHN) (Japan), 7. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo (Japan))
[F1-27]Identification of a novel immune regulatory mechanism involving WDR11
*WEI JIE CHEAH1, Gabriel Talaia1,2, Tsutomu Tanaka1,2, Koichi Kobayashi1,2,3 (1. Hokkaido University Graduate School of Medicine (Japan), 2. Hokkaido University Institute for Vaccine Research and Development (IVRED) (Japan), 3. Texas A&M Health Science Center (USA))
[F1-29]A Screening Platform for Natural Products Modulating IgA Secretion Based on Human IgA-Producing Hybridoma Clones
*Yuqing WU1,2, Zhongwei ZHANG1,2, Tamami MATSUSHITA1,2, Takuya NAKAGAWA3, Toyoyuki HANAZAWA3, Mariko KITAJIMA4, Hayato ISHIKAWA4, Hiroshi KIYONO2,5,6,7, Yosuke KURASHIMA1,2,5,8 (1. Department of Innovative Medicine, Graduate School of Medicine, Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba (Japan), 2. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba (Japan), 3. Department of Otorhinolaryngology, Head and Neck Surgery, Chiba University, Graduate School of Medicine, Chiba (Japan), 4. Laboratory of Natural Products and Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University (Japan), 5. Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine, San Diego, CA (USA), 6. Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba (Japan), 7. Division of Comparative Pathology and Medicine, Department of Pathology, University of California, San Diego, CA (USA), 8. Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba,University, Chiba (Japan))
[F1-31]Identification of Prognostic Biomarkers and Therapeutic Targets for Severe Respiratory Diseases using an Influenza Mouse Model
*Saya Kuribayashi1, Yuko Arita2, Toshinori Endo2, Yuichi Koshiishi3, Marumi Ohno3, Masashi Shingai3, Kiyoshi Takayama1 (1. NB health laboratory co. ltd (Japan), 2. Information Science and Technology, Hokkaido University (Japan), 3. International Institute for Zoonosis Control, Hokkaido University (Japan))
[F1-33]Presenting MHC II determines fidelity of SARS-CoV-2 spike peptide predicted binding
*Charles Schutt1, Deren Birol1, Xiuyuan Lu1, Sho Yamasaki1,2,3 (1. Immunology Frontier Research Center (IFReC), The University of Osaka (Japan), 2. Research Institute for Microbial Diseases (RIMD), The University of Osaka (Japan), 3. Center for Infectious Disease Education and Research (CiDER), The University of Osaka (Japan))
[F1-35]Study of cryopreservation solutions for maintaining the viability of malaria parasite sporozoites
*Hiroaki Matsumori1,2,3, Mariana Silva Almeida1,2,3, Cevayir Coban1,2,3 (1. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo (Japan) (Japan), 2. International Vaccine Design Center, Institute of Medical Science (IMSUT), University of Tokyo (Japan) (Japan), 3. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo (Japan) (Japan))
[F1-37]TLR7 Stress Response Disrupts Immune Privilege and Triggers
Submandibular Sialadenitis
*Takuma Shibata1, Kensuke Miyake2, Emi K Nishimura1 (1. Division of Aging and Regeneration, The Institute of Medical Science, The University of TOKYO (Japan), 2. Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University (Japan))
[F1-39]Mechanism of GC B cell differentiation into memory B cell
*Takeshi Inoue1 (1. The UTOPIA Center, The University of Tokyo (Japan))
[F1-41]Identification of commensal bacteria-derived molecules that are important for a subset of γδT cells
*Shunka Kano1, Ichita Hasegawa1, Yukihiro Endo1, Motoko Kimura1 (1. Graduate School of Medicine, Chiba University (Japan))
[F1-43]Uncovering genetic regulators of phagocytosis via large-scale CRISPR-Cas9 screens in human monocytic cells.
*Carlos le Sage1, Makoto Suematsu1 (1. Central Institute for Experimental Medicine and Life Science (Japan))
[F1-45]Development of a PEG Substitute Lipid for LNP Formulations to Reduce Immunogenic Risk Associated with Anti-PEG Antibodies
*Hirano Ayaka1, Matsumoto Makoto1, Mukai Hidefumi1, Kawakami Shigeru1 (1. Nagasaki University (Japan))
[F1-47]Recovery of Infectious Recombinant Human Norovirus Using Zebrafish Embryos
*Tomohiro Kotaki1, Yuki Akieda1, Zelin Chen1, Megumi Onishi1, Sayuri Komatsu1, Daisuke Motooka1, Hiroko Omori1, Shigeyuki Tamiya2, Yuta Kanai1, Shohei Minami1, Takahiro Kawagishi1,3, Naomi Sakon4, Shintaro Sato2, Tohru Ishitani1,5, Takeshi Kobayashi1,3,5 (1. Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Wakayama Medical University (Japan), 3. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 4. Osaka Institute of Public Health (Japan), 5. Center for Infectious Disease Education and Research, The University of Osaka (Japan))
[F1-49]Genome-wide CRISPR-A screening reveals AXL, a novel host factor involved in SFTSV entry
*ZECHENG JIN1,2,3, Shuhei Taguwa1,2,3, Junki Hirano2,3, Kentaro Uemura1,2,3, Chikako Ono1,2,3, Akatsuki Saito4, Tamaki Okabayashi4, Yusuke Maeda3, Taroh Kinoshita3,2, Yoshiharu Matsuura1,3,2 (1. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 2. Center for Infectious Disease Education and Research (CiDER) (Japan), 3. Research Institute for Microbial Diseases (RIMD) (Japan), 4. Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki (Japan))
[F1-51]Determining the host tropism of novel coronaviruses using AI protein structure predictions
Jarel Elgin Tolentino1, Victoria A. Jefferson2, Nicholas J. Catanzaro3, Ralph S. Baric3, Michael Letko2, *Spyros Lytras1, Kei Sato1 (1. The Institute of Medical Science, The University of Tokyo (Japan), 2. Paul G. Allen School for Global Health, Washington State University (USA), 3. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill (USA))
[F1-53]An mRNA-LNP vaccine induces cross-protective immunity against emerging H5N1 influenza viruses in mice
*Shintaro Shichinohe1, Qingxin Li1, Hiroki Tanaka2,3, Jessica Anindita3, Sara Yoshimoto1, Kaewaroon Nantaporn1,4, Makoto Shimooka1, Itsuki Anzai1, Hidetaka Akita2,3, Tokiko Watanabe1,2,5 (1. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 3. Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University (Japan), 4. The National Vaccine Institute (Thailand), 5. Center for Infectious Disease Education and Research (CiDER), The University of Osaka (Japan))
[F1-55]Identification and application of the packaging signals using reverse genetics for rotavirus
*Shohei Minami1, Yuta Kanai1, Hiroto Aoyama1, Kanako Matsumura1, Katsuhisa Hirai1, Sayuri Komatsu1, XueYing Li1, Zelin Chen1, Shizuka Sonoda1, Takahiro Kawagishi1,2, Tomohiro Kotaki1, Takeshi Kobayashi1,2,3 (1. Department of Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 3. Center for Infectious Disease Education and Research, The University of Osaka (Japan))
[F1-57]Mechanistic Analysis of Broadly Neutralizing Antibodies Against Diverse SARS-CoV-2 Variants
*Mizuki Yamamoto1, Yoko Hirayama1, Jun-ichiro Inoue2, Yasushi Kawaguchi1,3, Xuenan Xuan1 (1. Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo (Japan), 2. The University of Tokyo Pandemic preparedness, Infection and Advanced research center (UTOPIA), The University of Tokyo (Japan), 3. Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan))
[F1-59]Isolation of Lassa virus glycoprotein variants resistant to a neutralizing antibody using a conditionally replicating glycoprotein-encoding retroviral vector in BSL2
*Yoshinao Kubo1, Manya Bakatumana Hans1, Hironori Sato2, Osamu Kotani2 (1. Institute of Tropical Medicine, Nagasaki University (Japan), 2. National Institute of Infectious Diseases (Japan))
[F1-61]Identification of viral determinants underlying differences in the multiplication of Chikungunya and O'nyong-nyong viruses in mosquito vector cells using a rapid reverse genetics system
*Ryotaro Nouda1,2, Masaharu Iwasaki1,2,3,4 (1. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 2. Research Institute for Microbial Diseases, The University of Osaka (Japan), 3. Center for Infectious Disease Education and Research, The University of Osaka (Japan), 4. RNA Frontier Science Division, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka (Japan))
[F1-63]Establishment of a lethal mouse model for Oz virus infection and its application for antiviral drug and vaccine evaluation
*Rio Harada1,2, Cassia Sousa Moraes1,2, Atsuko Inoue1,3, Chilekwa Kabamba1,2, Joshua Kranrod1,4, Shuichi Osawa5, Motohito Goto6, Koshiro Tabata1, Shinji Saito1, Gabriel Gonzalez 1, Noriko Nagata5, Mamoru Ito6, Makoto Suematsu6, Hideki Hasegawa1,7, Hirofumi Sawa1,8,9, Yukari Itakura1 (1. Institute for Vaccine Research and Development, Hokkaido University (Japan), 2. Graduate School of Infectious Diseases, Hokkaido University (Japan), 3. Faculty of Pharmaceutical Science, Graduate School of Life Science, Hokkaido University (Japan), 4. Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University (Japan), 5. Ibaraki Prefectural Institute of Public Health (Japan), 6. Central Institute for Experimental Medicine and Life Science (Japan), 7. National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 8. International Institute for Zoonosis Control, Hokkaido University (Japan), 9. One Health Research Center, Hokkaido University (Japan))
[F1-65]Development of a High-Throughput Neutralization Assay for Orthoflaviviruses
*Kaito Maeda1, Atsuko Inoue1,2, Chinatsu Nakamura1, Yukari Itakura1, Shinji Saito1, Hirofumi Sawa1,3,4, Koshiro Tabata1 (1. Institute for Vaccine Research and Development, The University of Hokkaido (Japan), 2. Faculty of Pharmaceutical Science, Graduate School of Life Science, Hokkaido University (Japan), 3. International Institute for Zoonosis Control, Hokkaido University (Japan), 4. One Health Research Center, Hokkaido University (Japan))
[F1-67]Paramyxovirus-based Platforms for the Development of Henipavirus Vaccines
*Yuying WANG1, Taishi Onodera2, Yuki Kitai1, Yukiko Akahori1, Hekai Yang1, Hiroshi Katoh1, Akihide Ryo2, Katsumi Maenaka3, Takao Hashiguchi4, Junki Maruyama5, Yoshimasa Takahashi2, Makoto Takeda1 (1. The University of Tokyo (Japan), 2. Japan Institute for Health Security, National Institute of Infectious Diseases (Japan), 3. Hokkaido University (Japan), 4. Kyoto University (Japan), 5. University of Texas Medical Branch (USA))
[F1-69]Generating leukemia-directed T cell immunity by using allogeneic iPS cell-derived invariant NKT cells
*Takahiro Aoki1 (1. Department of Medical Immunology, Chiba University (Japan))
[F1-71]Efficacy of an attenuated vaccinia virus DIs against mpox in the mouse model
*Kenichi Otaki1, Fumihiro Yasui2, Hirohito Ishigaki1, Naoko Kitagawa1, Michinori Kohara2, Koji Ishii3, Yasushi Itoh1 (1. Division of Pathogenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science (Japan), 2. Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science (Japan), 3. Department of Quality Assurance and Radiological Protection, National Institute of Infectious Diseases (Japan))
[F1-73]Reciprocal roles of interleukin-33 in a lipid nanoparticle mRNA vaccine-induced cytotoxic T cell and type 2 responses
*Kaiwen Liu1,2,3, Kouji Kobiyama1,2,3,8, Naoko Satoh-Takayama4, Tomoya Hayashi1,2,3, Burcu Temizoz1,2,3, Hideo Negishi1,2,3,5, Asuka Joy Tobuse1, Mai Onaga1, Peter D Katsikis6, Cevayir Coban2,3,7, Ken J Ishii1,2,3 (1. Division of Vaccine Science, IMSUT (Japan), 2. International Vaccine Design Center, IMSUT (Japan), 3. The UTOPIA Center, The University of Tokyo (Japan), 4. Precision Immune Regulation RIKEN ECL Research Unit, RIKEN Center for Integrative Medical Sciences (Japan), 5. Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, the University of Tokyo (Japan), 6. Department of Immunology, Erasmus University Medical Center (Netherlands), 7. Division of Malaria Immunology, the Institute of Medical Science, IMSUT (Japan), 8. Division of Rheumatology, Department of Medicine, University of California San Diego (USA))
[F1-75]Mechanistic dissection of IVReD vaccine candidate-induced protection against tuberculosis
*Shunsuke Sakai1, Satoru Mizuno1, Kazuhiro Matsuo1, Yasuhiro Yasutomi1,2 (1. IVReD, Hokkaido University (Japan), 2. Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan))
[F1-77]Analysis of signaling pathways that induce mRNA vaccine-induced IL-6 production
*Yuji Kubota1, Takekawa Mutsuhiro1 (1. Division of Cell Signaling and Molecular Medicine, Institute of Medical Science, The University of Tokyo (Japan))
[F1-79]Investigation of the protection against tuberculosis by adjuvant-containing live-attenuated AIDS virus
*Yoshiaki Shibukawa1,2, Natsuko Yamakawa1, Emiko Urano1, Yasuhiro Yasutomi1 (1. Tsukuba primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan), 2. Osaka university (Japan))